ArticleBMC ophthalmology2026
Association between capsulectomy shunt revision and Ahmed glaucoma valve implant exposure--Shanghai Ahmed glaucoma valve implant exposure (AGVIE) study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe Ahmed Glaucoma Valve (AGV) is a drainage device commonly used in the treatment of refractory glaucoma. Implant exposure is a major cause of surgical failure. This study aimed to identify factors associated with AGV exposure.
methodsThis retrospective cohort study included all inpatients who underwent primary AGV implantation at the Eye & ENT Hospital of Fudan University between January 2015 and December 2024. Baseline demographic and surgical data were collected. Factors associated with AGV exposure were evaluated using univariate and multivariate logistic regression.
resultsIn this comprehensive cohort study, involving a total of 2,905 eyes, with participants having a mean age of 49.2 ± 18.0 years and 64% being male, we observed that AGV exposure occurred in 75 eyes, accounting for an incidence rate of 2.6% (95% CI, 2.0-3.2%). Capsulectomy shunt revision (CSR) was associated with AGV exposure in both univariable analysis (OR 3.72, 95% CI 1.73-7.98; P < 0.001) and multivariable analysis (OR 3.95, 95% CI 1.79-8.69; P < 0.001).
conclusionsThe crude incidence of AGV exposure was 2.6%. CSR was statistically associated with AGV exposure, although this finding should be interpreted cautiously given the retrospective design and methodological limitations. Careful surgical planning and close postoperative monitoring may therefore be warranted. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.